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Abstract
To report the implementation, dosimetric results of and early experiences with stereotactic accelerated partial breast irradiation
(SAPBI) following breast conserving surgery (BCS) for postmenopausal low-risk St I-II invasive breast cancer (IBC) patients.
Between November 2018 and August 2019, 27 patients were registered in our phase II prospective study. SAPBI was performed
with Cyber-Knife (CK) M6 machine, in 4 daily fractions of 6.25 Gy to a total dose of 25 Gy. Respiratory movements were
followed with implanted gold markers and Synchrony system. Corrections for patient displacement and respiratory movement
during treatment were performed with the robotic arm. Early side effects, cosmetic results, and dosimetric parameters were
assessed. The average volume of the surgical cavity, clinical target volume (CTV), and planning target volume (PTV_EVAL)
were 8.1 cm3 (range: 1.75–27.3 cm3), 55.3 cm3 (range: 26.2–103.5 cm3), and 75.7 cm3 (range: 40–135.4 cm3), respectively. The
mean value of the PTV_eval/whole breast volume ratio was 0.09 (range: 0.04–0.19). No grade 2 or worst acute side-effect was
detected. Grade 1 (G1) erythema occurred in 6 (22.2%) patients, while G1 oedema was reported by 3 (11.1%) cases. G1 pain was
observed in 1 (3.4%) patient. Cosmetic result were excellent in 17 (62.9%) and good in 10 (37.1%) patients. SAPBI with CK is a
suitable and practicable technique for the delivery of APBI after BCS for low-risk, St. I-II. IBC. Our early findings are
encouraging, CK-SAPBI performed with four daily fractions is convenient and perfectly tolerated by the patients.
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Introduction
The most frequent malignancy among women in industrial-
ized countries is breast cancer (BC). According the WHO
627,000 women died from BC worldwide – which is almost
15% of all cancer deaths among women in 2018 (https://www.
who.int/cancer/prevention/diagnosis-screening/breast-cancer/
en/). Due to the introduction of mammography screening and
more effective oncological treatments, BC mortality shows a
downward trend. Several prospective randomized studies
demonstrated that in early-stage BC patients whole breast ir-
radiation (WBI) following breast conserving surgery (BCS)
not only reduces the proportion of local recurrences (LR) in
the ipsilateral breast, but also improves overall survival [1–3].
The rationale for WBI is the eradication of residual micro-
scopic disease after lumpectomy. However, WBI exposes
the skin, lung, chest wall, and heart to high doses of radiation.
The theory of accelerated partial breast irradiation (APBI)
stems from two reasons. First, the predominance of LR’s after
BCS are near to the original primary tumour site. According to
the pathological studies of Holland et al., multicentricity oc-
curred in a significant proportion of BC’s, therefore, WBI was
the standard treatment after BCS [4]. Later, other pathological
studies demonstrated that in a unicentric, unifocal tumour
(without extensive intraductal component or invasive lobular
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pathological subtype), microscopic tumour cells can be found
only in 2–4% at >1.5–2 cm distance from the index tumour,
and following WBI the ipsilateral breast recurrence rate was
almost equivalent to the rate of contralateral carcinomas [5, 6].
Second, even in developed countries, radiotherapy units are
not available in all cities, therefore, the five-days-a-week oc-
casions for 3 to 7 weeks treatment schedule may expect pa-
tients to omit work and can lead to other daily routine sever-
ances. Almost 20% of patients with early-stage IBC and treat-
ed with BCS choose to forgo the radiation therapy in the
United States [7]. To minimalize the treatment schedule from
3 to 7 weeks to 1 week or less is another advantage of APBI.
These pathological findings and the clinical eagerness to ab-
breviate the course of breast radiotherapy and decrease the
toxicity of normal tissues led to the investigation of efficacy
and safety of APBI in prospective clinical trials [8–25]. In
these early studies, the inappropriate patient selection criteria,
quality control, and target definition led to very high (25–
37%) local relapse rates after 6–8 years [8, 9]. In later studies,
more favourable experiences accumulated using APBI with
interstitial brachytherapy (iBT), three-dimensional conformal
external beam radiotherapy (3D-CRT), and image-guided in-
tensity-modulated radiotherapy (IG-IMRT) in correctly select-
ed early-stage BC patients [10–25]. Stereotactic treatment ap-
proaches are emerging and are widely accepted in early stage
lung cancer, prostate cancer, or bone and brain metastasis
patients [26–29]. However, to date, only a few phase I/II stud-
ies were published with CyberKnife-based stereotactic APBI
(CK-SAPBI) [30–36].
In 2018, we initiated a phase II clinical study to test the
effectiveness and usefulness of CK-SAPBI with a four-
fraction schedule. SAPBI adopting real-time tracking, respira-
tory motion administration, and submillimetre efficiency of-
fers improvements in partial breast irradiation enabling great
dose conformality to target region [31, 36]. We report the
dosimetric parameters and the early clinical outcomes of this
prospective phase II clinical study using CK-SAPBI.
Patients and Methods
Between 2018 November and 2019 August, 27 early-
stage BC patients were treated with CK-SAPBI. Patient
eligibility criteria were the same as in our previous APBI
trials, and were reported in detail in our previous publi-
cations [19, 20, 22, 23]. Briefly, patients were eligible for
CK-SAPBI if they were 50 years old or older, with inva-
sive tumour up to a diameter of 3 cm, with negative ax-
illary lymph node status (pN0) and with clear surgical
margins by at least 2 mm. We omitted patients if they
had multiple or multifocal invasive tumour histology sub-
type Paget-disease, bilateral breast cancer, preliminary
history of BC or additional malignant disease within
5 years. Tumour and patient characteristics are presented
in Table 1. To identify the excision cavity and to guide
optimal fiducial placement, CT scanning of the operated
breast was performed with a 5 mm slice thickness. Only
patients with good identifiable cavity were eligible for the
study (visibility score (CVS) of 3–5) [37]. Prior to the
treatment, three to four gold fiducials were placed near
the surgical bed with ultrasound guidance by a certified
radiologist together with the treating radiation oncologist,
in local anaesthesia. For optimal tracking, the maximum
and minimum distances between fiducial markers were
less than 10 cm and more than 2 cm, and the markers
were placed at least 1–2 cm away from the seroma cavity,
as recommended by Seiler et al. [38]. One week after gold
marker placement, a new simulation CT was performed in
a supine position with both arms next to the body with
1.25 mm axial slice spacing. For delineating the target
volumes and organs at risks, the GEC-ESTRO Breast
Working Group recommendations were applied [39].
The surgical bed included the surgical clips were deter-
mined as the tumour bed. The clinical target volume
(CTV) was defined as the tumour bed+ (20 mm minus
the free surgical margins (in mm)) in six directions. The
CTV margin was confined at the breast parenchyma/
pectoral muscle interface and to 5 mm beneath the skin
surface and. A uniform, three-dimensional 2 mm margin
was added to the CTV to attain the planning target vol-
ume (PTV). For dosimetric reporting, the PTV_EVAL
was accomplished from the PTV limiting the PTV except
the first 5 mm of tissue from surface and any lung tissue
[15]. Daily localization and fiducial tracking were accom-
plished with the Synchrony Respiratory Tracking System
(Cyberknife, Accuray, Sunnyvale, CA). Light-emitting di-
odes (LED’s) were placed on the chest wall of the patients
and were tracked by an optical camera. Fifteen orthogonal
x-ray image pairs were acquired in different phases of the
breathing cycle. The fiducials were checked on each im-
age pair. A predictive correlation model was created be-
tween tumour bed positions – represented by the fiducials
– and the chest wall position. During beam delivery, the
radiation fields were always pointing at the position of the
PTV, according to the information obtained from the op-
tical camera signal. A minimum of 3 fiducial markers
were tracked at all times to avoid rotational errors. The
treatments were performed on a CyberKnife M6 machine
with MLC and step-and-shoot IMRT technique, with 57
segments on average (range: 34–76), and with a dose of
4 × 6.25 Gy (total dose: 25 Gy) on four consecutive days
(Figs. 1 and 2). Our equivalent dose calculations are listed
in Table 2, compared to other fractionations (10 × 3.4 Gy
and 7 × 4.3 Gy) frequently used by others in routine clin-
ical practice. Radiotherapy was started within 12 weeks
after surgery for all 27 patients. Hormone therapy was
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applied to all patients, 26 patients (96.6%) received aro-
matase inhibitors or goserelin acetate and tamoxifen in 1
case (3.4%). Within 7–14 days after the completion of
CK-SAPBI, the acute side effects were recorded accord-
ing to the Radiation Therapy Oncology Group/European
Society for Therapeutic Radiology and Oncology
(RTOG/EORTC) scoring system [40].
The study protocol was assessed and approved by the na-
tional ethics committee, and before recruitment all women
provided written informed consent.
Results
All patients received the planned four fractions of CK-SAPBI
with the predefined study-specific dose constraints. No proto-
col violation arose. At least three fiducials were tracked in all
cases. The mean size of the primary tumour was 11 mm
(range: 6–21 mm). The average volume of the surgical cavity,
CTV and PTV_EVAL was 8.1 cm3 (range: 1.75–27.3 cm3),
55.3 cm3 (range: 26.2–103.5 cm3), and 75.7 cm3 (range: 40–
135.4 cm3), respectively. The mean value of the PTV_eval/
whole breast volume ratio was 0.09 (range: 0.04–0.19). Dose-
volume parameters are listed in Table 3. The average values of
V100 for CTV and PTV_EVAL were 99.4% and 97.5%, re-
spectively. The mean Dmax value for PTV_EVAL was
116.5%. The mean V100, V75 and V50 of ipsilateral breast-
PTV was 0.73% (range: 0.3–1.4), 4.8% (range: 2–8.5%) and
10.8% (range: 5–18.9%) respectively. The mean ipsilateral
and contralateral lung dose (MLD) and D10% was 131 cGy
(range: 33–205 cGy) and 328 cGy (range: 68–524 cGy),
12 cGy (range: 3–44 cGy) and 29 cGy (range: 8–131 cGy),
respectively. The mean heart dose (MHD) and D0,04cm3 heart
was 89 cGy (range: 31–173 cGy) and 568 cGy (range: 216–
1094 cGy) for left-sided, and 34 cGy (range: 13–84 cGy) and
219 cGy (range: 90–436 cGy) for right-sided lesions, respec-
tively. The mean D0,01cm
3, and mean D 0,04cm3 skin and rib
doses was 2380 cGy (range: 1074–2866 cGy), 2338 cGy
(range: 1021–2839 cGy) and 2317 cGy (range: 978–2766),
2243 cGy (range: 952–2722 cGy) respectively. A typical treat-
ment plan are shown in Fugure 2.
At a median follow-up of 12 months (range: 8–17months),
no loco-regional recurrence or distant metastasis occurred,
and all patients are alive. Grade 2 or worse early side-effect
wasn’t detected. Grade 1 (G1) erythema occurred in 6 (22.2%)
patients, while G1 oedema, was reported in 3 (11.1%) cases.
G1 pain was observed by 1 (3.4%) patient. The cosmetic
Table 1 Patient, tumor and adjuvant treatment characteristics
Characteristics n (%)a




















Pathological tumour size (mm)
≤ 5 0 (0%)
> 5–10 12 (44.4%)




pN0 (SLNB) 27 (100%)
pN0 (ALND) 0 (0%)
Free surgical margins (mm)
≥ 2–5 12 (44.4%)
> 5–10 15 (55.6%)
> 10 0 (0%)
Histologic type






ER and PR + 26 (96.4%)
ER +, PR - 1 (3.6%)
ER -, PR + 0 (0%)







ER estrogen receptor, PR progesterone
a receptor Data are n (%) if not otherwise specified
Fig. 1 S-APBI with M6 Cyberknife machine
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outcome was excellent in 17 (62.9%), and good in 10 (30.1%)
patients. Cosmetic results and early side effects are listed in
Table 4. The average daily treatment time was 43 min (range:
33–68 min) door-to-door.
Discussion
At our institute, between November 2018 and August 2019,
27 patients were treated with SAPBI using a Cyber-Knife M6
machine, with four daily fractions. According to our early
experience, no patients have recurrence or fair/poor cosmesis.
APBI with appropriate patient selection and quality control
became a widely accepted treatment option for the treatment
of early-stage BC in highly qualified radiotherapy centres
[10–25]. In the GEC-ESTRO Breast Cancer Working
Group, multicentric randomised study iBT still prove the
Fig. 2 Cyber-Knife treatment planning images with the dose of 4 × 6.25 Gy. a-c isodose lines in three different planes. d illustration of pencil beam
trajectories
Table 3 Dose volumes parameters of organs at risks
Organs at risks
Mean Median (range)
Ipsilateral non-target breast (%)
V 100% 0.7 0.7 (0.3–1.4)
V 75% 4.8 4.3 (2.0–8.5)
V 50% 10.7 9.5 (5–18.9)
Contralateral breast
D 0.04 cm3 (cGy) 50.4 39 (13–172)
Mean dose (cGy)
Heart (left sided lesion)
D 0.04 cm3 (cGy) 568 477 (216–1094)
Mean dose (cGy) 89 83 (31–173)
Heart (right sided lesion)
D 0.04 cm3 (cGy) 219 201 (90–436)
Mean dose (cGy) 34 33 (13–84)
Ipsilateral lung
D 10% (cGy) 328.3 337 (68–524)
Mean dose (cGy) 131.6 129 (33–205)
Contralateral lung
D 5% (cGy) 38.8 31 (16–164)
Mean dose (cGy) 12.1 10 (3–44)
Skin
D 0.01 cm3 (cGy) 2380.1 2674 (1074–2866)
Rib
D 0.01 cm3 (cGy) 2317.4 2475 (978–2766)
Table 2 Calculations of equivalent doses in different fractionations
with using different α/β ratio
Total dose BED Gy4 BED Gy10 BED Gy2 EQD2 Gy4
10 × 3.4Gy 34 63 46 92 42
7 × 4.3Gy 30.1 63 43 96 41.6
4 × 6.25Gy 25 64 40.6 103 42.7
Biological equivalent dose (BED) and equivalent dose in 2 Gy per frac-
tion (EQD2) for tumour control and for normal tissue toxicity at each dose
level
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efficacy, feasibility, and quality of life after a 5-year follow-up.
But brachytherapy is invasive and needs a highly qualified
staff to perform [10–12]. In 2019, Vicini et al. presented the
10-year results of the NSABP B-39/RTOG 0413 phase III
APBI study in the Lancet [41]. The 10-year cumulative inci-
dence of IBTR between APBI andWBI was only 0.7% (4.6%
vs 3.9%) with a hazard ratio (HR) of 1.22 (90%CI 0.94–1.58),
this difference in IBTR was less than 1% at 10 years, suggest-
ing that APBI is an acceptable option for a proportion of
women who undergo BCS. There were no statistically signif-
icant differences in late G3–5 toxicities. In the same issue of
the Lancet, the long-term results of the RAPID 3D-CRTAPBI
trial were also presented byWhelan et al. [42]. After 8.6 years
of median follow-up, the LR rate was 2.8% in the WBI, and
3% in the PBI arm, but the difference was not statistically
significant [HR = 1.27 (90%CI, 0.84–1.91)]. Grade 2 and
grade 3 late side effects were 28% and 4% in PBI and 12%
and 1% in the WBI arm, the 7-year fair and poor cosmetic
results were 31% vs 15%, respectively. The five-year results
of the Italian prospective randomized study have presented
that the 5-year local tumour control was equivalent with
APBI or WBI, 1.5% local recurrence rate in both arms [43].
Concerning acute side effects, the APBI group showed signif-
icantly better results in any grade (p = 0.0001) and grade 2 or
higher (p = 0.0001) cases. APBI with 3D-CRT or IG-IMRT
are non-invasive techniques in contrast to iBT.
Recently, CK has emerged as a possible alternative to con-
ventional APBI techniques. CyberKnife offers advantages of
iBT and external beam APBI. The dose profile of CK is com-
parable to brachytherapy because of the steep dose gradient
with small PTV volumes, and it is a non-invasive method. The
CK respiratory tracking system allows treatment to be deliv-
ered while also considering the patient’s breath motions.
Many publications have noted higher rates of late toxicity
and/or poorer cosmetic results following APBI delivered with
3D-CRT or IMRT compared to WBI [14, 18, 37, 44, 45].
Hepel et al. [37] reported 8.3% rate of grade 3–4 subcutaneous
fibrosis after a median follow-up of 15 months. Shah et al.
[14] also published a 7.5% rate of grade 3–4 fibrosis after
5 years. In these studies, the higher rate of late toxicity was
probably due to the voluminous irradiated target, since the
PTV values were in the range of 175 to 330 cm3. To minimize
the amount of the treated volume, we performed real-time
image guidance during each fraction. Using the Synchrony
system, the CTV-PTV margins could be decreased to 2 mm
obtain a limited mean target volume (PTV_EVAL) of
75.7 cm3. In contrast, in our previous APBI study using IG-
IMRT technique without real-time tracking and using a 5 mm
CTV-PTV margin, the mean treatment volume (PTV_EVAL)
was 152.6 cm3 which is twice the volume obtained in this
study using CK-SAPBI [22].
A very limited number of phase I or II prospective study
have been published with CK-SAPBI [30–36]. One of the
earliest studies published by Vermuelen et al. in 2011 reported
46 patients treated with CK-SAPBI [31]. The first two patients
were treated with 5 fractions of 5 Gy each, thereafter the
patients received 10 times 3.4 Gy to the PTV, recommended
to the 65–75% isodose-line. After 12 patients, the prescribed
dose was increased to 10 times 3.6 Gy. The mean percent
isodose prescription line was 70% (range, 65–76%) to the
PTV, the mean PTV was 114 cm3 (range, 39–241 cm3).
After a mean follow-up of 31 months (range, 6–57 months),
no BC recurrence was recorded. Very mild toxicities occurred,
100% of the patients had good-excellent cosmesis. Lozza et al.
published a pilot study in 2018, they treated 20 patients with
CK-SAPBI using the Iris collimator [32]. The total dose was
30 Gy in 5 consecutive fractions and were prescribed to the
isodose line include 95% of the PTV. After a 2-year median
follow-up, no recurrence occurred, a mean 88.1 cm3 PTVwas
treated with mild acute and late side effects, and more than
80% of cases ended with excellent cosmetic results. The total
patient treatment time comprised patient set-up was around
60 min (range: 35–120 min). In 2016, 10 patients received
CK-SAPBI in Georgetown University Hospital [30]. A 5
mm safety margin was added to CTV to generate PTV, and
they use the same treatment schedule as previously described
(30 Gy in five fractions). The mean prescription isodose line
was 80% to the PTV, and the mean treated PTV was 70 cm3,
100% of the PTV received the prescription dose (PTV30).
After the treatments mild toxicity was reported. At a median
follow-up of 1.3 years, no breast events have been document-
ed, and all patients had excellent/good cosmetic results.
There are some potential disadvantages of CK-SAPBI. The
impalement of the fiducials is an invasive intervention.
Fiducial movement can appear after placement, therefore our
practice is to wait at least 1 week following fiducial implan-
tation. CK-SAPBI daily treatment times are lengthened com-
pared to another external beam APBI 10–15 min treatments.
In our study, the mean treatment time was 43 min (range: 33–
68 min). We observed a learning curve meaning a continuous-
ly decreasing door to door treatment time as our experience
has grown. The smaller treatment volume and less toxicities
are the trade-offs for the relatively longer treatment time.
Table 4 Early radiation side effects and cosmetic results
Grade 0 Grade 1 Grade 2 Grade 3–4
Early side effect
Skin 21 (77.8%) 6 (22.2%) 0 (0%) 0 (0%)
Breast parenchyma 24 (89.9%) 3 (11.1%) 0 (0%) 0 (0%)
Pain 26 (96.6%) 1 (3.4%) 0 (0%) 0 (0%)
Excellent Good Fair Poor
Cosmetic result
Rated by physicians 17 (61.9%) 10 (30.1%) 0 (0%) 0 (0%)
Rated by patients 16 (59.3%) 11 (40.7%) 0 (0%) 0 (0%)
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Conclusions
SAPBI with CK is a suitable and practicable technique for the
delivery of APBI after BCS for low-risk, St. I-II. IBC. Our early
findings are encouraging, CK-SAPBI delivered with four daily
fractions is convenient and perfectly tolerated by the patients.
Longer follow-up and a higher number of patients are needed
to validate the late toxicity and tumour control results.
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